Isocitrate Dehydrogenase Mutations in Gliomas: Mechanisms, Biomarkers and Therapeutic Target

Overview

Journal Curr Opin Neurol

Specialty Neurology

Date 2011 Oct 18

PMID 22002076

Citations 47

Authors

Changcun Guo

Christopher J Pirozzi

Giselle Y Lopez

Hai Yan

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Isocitrate dehydrogenases, IDH1 and IDH2, decarboxylate isocitrate to α-ketoglutarate (α-KG) and reduce NADP to NADPH. Point mutations of IDH1 and IDH2 have been discovered in gliomas. IDH mutations cause loss of native enzymatic activities and confer novel activity of converting α-KG to 2-hydroxyglutarate (2-HG). The mechanisms of IDH mutations in gliomagenesis, and their value as diagnostic, prognostic marker and therapeutic target have been extensively studied. This review is to summarize the findings of these studies.

Recent Findings: Crystal structural studies revealed conformation changes in mutant IDHs, which may explain the gain of function by mutant IDHs. The product of mutant IDHs, 2-HG, is an inhibitor of α-KG-dependent dioxygenases, which may cause genome-wide epigenetic changes in human gliomas. IDH mutations are a favorable prognostic factor for human glioma and can be used as biomarker for differential diagnosis and subclassification rather than predictor of response to treatment. Preliminary data suggested that inhibiting production of the substrate of mutant IDH enzymes caused slow-down of glioma cell growth.

Summary: As valuable diagnostic and prognostic markers of human gliomas, there is still a lack of knowledge on biological functions of mutant IDHs, making targeting IDHs in glioma both difficult and unsecured.

Citing Articles

Oncometabolite 2-hydroxyglutarate suppresses basal protein levels of DNA polymerase beta that enhances alkylating agent and PARG inhibition induced cytotoxicity.

Saville K, Al-Rahahleh R, Siddiqui A, Andrews M, Roos W, Koczor C DNA Repair (Amst). 2024; 140:103700.

PMID: 38897003 PMC: 11239280. DOI: 10.1016/j.dnarep.2024.103700.

Potential Diagnostic and Clinical Significance of Selected Genetic Alterations in Glioblastoma.

Tomoszkova S, Skarda J, Lipina R Int J Mol Sci. 2024; 25(8).

PMID: 38674026 PMC: 11050250. DOI: 10.3390/ijms25084438.

Identification of a robust biomarker LAPTM4A for glioma based on comprehensive computational biology and experimental verification.

Ding Y, Jiang Y, Zeng H, Zhou M, Zhou X, Yu Z Aging (Albany NY). 2024; 16(8):6954-6989.

PMID: 38613802 PMC: 11087115. DOI: 10.18632/aging.205736.

Grade 2, 3 and Dedifferentiated Chondrosarcomas: A Comparative Study of Isocitrate Dehydrogenase-Mutant and Wild-Type Tumors with Implications for Prognosis and Therapy.

Schoedel K, Heim T, Duensing A, Lohse I, Presutti L, Belayneh R Cancers (Basel). 2024; 16(2).

PMID: 38254737 PMC: 10813891. DOI: 10.3390/cancers16020247.

IDH1/MDH1 deacetylation promotes acute liver failure by regulating NETosis.

Wang Y, Shi C, Guo J, Zhang D, Zhang Y, Zhang L Cell Mol Biol Lett. 2024; 29(1):8.

PMID: 38172700 PMC: 10765752. DOI: 10.1186/s11658-023-00529-7.

References

Felsberg J, Wolter M, Seul H, Friedensdorf B, Goppert M, Sabel M . Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol. 2010; 119(4):501-7. DOI: 10.1007/s00401-010-0647-4. View

Horbinski C, Kofler J, Yeaney G, Camelo-Piragua S, Venneti S, Louis D . Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas. Brain Pathol. 2011; 21(5):564-74. PMC: 3681126. DOI: 10.1111/j.1750-3639.2011.00480.x. View

Ward P, Patel J, Wise D, Abdel-Wahab O, Bennett B, Coller H . The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 17(3):225-34. PMC: 2849316. DOI: 10.1016/j.ccr.2010.01.020. View

Sjoblom T, Jones S, Wood L, Parsons D, Lin J, Barber T . The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314(5797):268-74. DOI: 10.1126/science.1133427. View

Narasimhaiah D, Miquel C, Verhamme E, Desclee P, Cosnard G, Godfraind C . IDH1 mutation, a genetic alteration associated with adult gliomatosis cerebri. Neuropathology. 2011; 32(1):30-7. DOI: 10.1111/j.1440-1789.2011.01216.x. View

Lopez G, Reitman Z, Solomon D, Waldman T, Bigner D, McLendon R . IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochem Biophys Res Commun. 2010; 398(3):585-7. PMC: 2987603. DOI: 10.1016/j.bbrc.2010.06.125. View

Mardis E, Ding L, Dooling D, Larson D, McLellan M, Chen K . Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009; 361(11):1058-66. PMC: 3201812. DOI: 10.1056/NEJMoa0903840. View

Pollack I, Hamilton R, Sobol R, Nikiforova M, Lyons-Weiler M, LaFramboise W . IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group. Childs Nerv Syst. 2010; 27(1):87-94. PMC: 3014378. DOI: 10.1007/s00381-010-1264-1. View

Yan H, Parsons D, Jin G, McLendon R, Rasheed B, Yuan W . IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360(8):765-73. PMC: 2820383. DOI: 10.1056/NEJMoa0808710. View

10.

Kil I, Chung K, Park J . Silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase gene enhances selenite-induced apoptosis. Free Radic Res. 2010; 44(3):332-9. DOI: 10.3109/10715760903494184. View

11.

Metellus P, Colin C, Taieb D, Guedj E, Nanni-Metellus I, Maues de Paula A . IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. J Neurooncol. 2011; 105(3):591-600. DOI: 10.1007/s11060-011-0625-2. View

12.

Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A . Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009; 118(4):469-74. DOI: 10.1007/s00401-009-0561-9. View

13.

Desestret V, Ciccarino P, Ducray F, Criniere E, Boisselier B, Labussiere M . Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression. J Neurooncol. 2011; 105(2):219-24. DOI: 10.1007/s11060-011-0587-4. View

14.

Boisselier B, Marie Y, Labussiere M, Ciccarino P, Desestret V, Wang X . COLD PCR HRM: a highly sensitive detection method for IDH1 mutations. Hum Mutat. 2010; 31(12):1360-5. DOI: 10.1002/humu.21365. View

15.

Meyer J, Pusch S, Balss J, Capper D, Mueller W, Christians A . PCR- and restriction endonuclease-based detection of IDH1 mutations. Brain Pathol. 2009; 20(2):298-300. PMC: 8094690. DOI: 10.1111/j.1750-3639.2009.00327.x. View

16.

Capper D, Sahm F, Hartmann C, Meyermann R, von Deimling A, Schittenhelm J . Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol. 2010; 34(8):1199-204. DOI: 10.1097/PAS.0b013e3181e7740d. View

17.

Gross S, Cairns R, Minden M, Driggers E, Bittinger M, Jang H . Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010; 207(2):339-44. PMC: 2822606. DOI: 10.1084/jem.20092506. View

18.

Schnittger S, Haferlach C, Ulke M, Alpermann T, Kern W, Haferlach T . IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood. 2010; 116(25):5486-96. DOI: 10.1182/blood-2010-02-267955. View

19.

Noushmehr H, Weisenberger D, Diefes K, Phillips H, Pujara K, Berman B . Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010; 17(5):510-22. PMC: 2872684. DOI: 10.1016/j.ccr.2010.03.017. View

20.

Kang M, Kim M, Oh J, Kim Y, Song S, Seo S . Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer. 2009; 125(2):353-5. DOI: 10.1002/ijc.24379. View